Trial Outcomes & Findings for COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana (NCT NCT04939506)

Last Updated: 2026-07-21

Results Overview

COVID-19 vaccination completion verified by the Louisiana LINKS© system, defined as receipt of all recommended doses of a COVID-19 vaccine during the 9-month intervention period following education at the point of COVID-19 testing.

Recruitment status

COMPLETED

Study phase

Target enrollment

377 participants

Primary outcome timeframe

9 months intervention

Results posted on

2026-07-21

Participant Flow

Participant milestones

Participant milestones
Measure	Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans. COVID-19 Vaccine Education at the Point of COVID-19 Testing: A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
Overall Study STARTED	377
Overall Study COMPLETED	309
Overall Study NOT COMPLETED	68

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing n=377 Participants Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
Age, Categorical <=18 years	14 Participants n=9 Participants
Age, Categorical Between 18 and 65 years	343 Participants n=9 Participants
Age, Categorical >=65 years	20 Participants n=9 Participants
Sex: Female, Male Female	143 Participants n=9 Participants
Sex: Female, Male Male	234 Participants n=9 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	47 Participants n=9 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	330 Participants n=9 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=9 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=9 Participants
Race (NIH/OMB) Asian	0 Participants n=9 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=9 Participants
Race (NIH/OMB) Black or African American	150 Participants n=9 Participants
Race (NIH/OMB) White	170 Participants n=9 Participants
Race (NIH/OMB) More than one race	57 Participants n=9 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=9 Participants
Region of Enrollment United States	377 Participants n=9 Participants
participants received covid-19 test or not Received COVID-19 test	308 Participants n=9 Participants
participants received covid-19 test or not did not receive COVID-19 test	69 Participants n=9 Participants
Received COVID-19 Vaccine Before Study Started Between 2020-2022 Received Covid-19 Vaccine Prior to Study 2020-2022	170 Participants n=9 Participants
Received COVID-19 Vaccine Before Study Started Between 2020-2022 Did not receive Covid-19 Vaccine Prior to Study 2020-2022	207 Participants n=9 Participants

PRIMARY outcome

Timeframe: 9 months intervention

Outcome measures

Outcome measures
Measure	Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing n=309 Participants Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
COVID-19 Vaccine Completion Upon Education Did receive bivalent COVID-19 vaccination since education	9 Participants
COVID-19 Vaccine Completion Upon Education Did not receive bivalent COVID-19 vaccination since education	300 Participants

SECONDARY outcome

Timeframe: 9 months post intervention

Measured on a 5-point scale indicating likelihood to be vaccinated. The scale ranges from 1 (Not at all likely to be vaccinated), 2 (Not likely to be vaccinated), 3 (No opinion/Undecided about vaccination), 4 (Likely to be vaccinated) to 5 (Very likely to be vaccinated)

Outcome measures

Outcome measures
Measure	Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing n=309 Participants Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
Vaccine Hesitancy Likelihood Scale Very Unlikely	102 Participants
Vaccine Hesitancy Likelihood Scale Unlikely	59 Participants
Vaccine Hesitancy Likelihood Scale Somewhat	76 Participants
Vaccine Hesitancy Likelihood Scale Likely	27 Participants
Vaccine Hesitancy Likelihood Scale Very Likely	45 Participants

Adverse Events

Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sara Al-Dahir

Xavier University of Louisiana

Phone: (504) 520-7971

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place